Bristol Myers, Ono Sue Amgen to Block Proposed Opdivo Biosimilar in US
Washington: Bristol Myers Squibb and Ono Pharmaceutical have sued Amgen in Delaware federal court, seeking to block Amgen's proposed U.S. biosimilar of their blockbuster cancer immunotherapy drug Opdivo.
The lawsuit, filed last week and made public on Monday, alleges that Amgen's biosimilar would infringe several patents.
Opdivo earned Bristol Myers more than $5.9 billion in revenue in the United States last year, according to a company report.
An Amgen spokesperson on Tuesday declined to comment on the lawsuit but said the company has applied for U.S. Food and Drug Administration approval of its drug and "remains confident" that it will be "in the first wave of Opdivo biosimilars."
Spokespeople for Bristol Myers and Ono did not immediately respond to requests for comment.
Biosimilars are based on existing versions of biologic drugs and are comparable to generic versions of traditional pharmaceuticals. Unlike traditional drugs, complex biologics are made from living cells and cannot be copied exactly.
Bristol Myers and Ono, which co-developed Opdivo, allege that Amgen's biosimilar would infringe seven U.S. patents covering the drug, and asked the court to block sales of the biosimilar while their patents remain in force.
Opdivo has been approved in the U.S. to treat advanced or metastatic cancers, including ​melanoma, non-small cell lung cancer and kidney cancer.
Bristol Myers and Ono settled a patent dispute with Merck in 2017 over its rival blockbuster cancer drug Keytruda. Under the settlement, Merck agreed to pay $625 million and a share of Keytruda royalties through 2023.
Bristol Myers said in a report filed with the U.S. Securities and Exchange Commission in February that it expects to maintain patent exclusivity over Opdivo until 2028.
The case is Bristol-Myers Squibb Co. v. Amgen Inc., U.S. District Court for the District of Delaware, No. 1:26-cv-01134.
For BMS and Ono: Steven Maslowski of Akin Gump Strauss Hauer & Feld
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.